Amphastar Pharmaceuticals, Inc. reported $730M of revenue over the trailing twelve months, +1.0% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $730M (to Q2 2026). Net income: $79M, trailing twelve months to Q2 2026. Free cash flow: $153M, trailing twelve months to Q2 2026. Operating margin: 16%, trailing twelve months to Q2 2026.

AMPHAmphastar Pharmaceuticals, Inc.

Healthcare

$25.83+0.00% 1Y

$25.83

$16.8752 weeks$29.40

AMPH as reported

Amphastar Pharmaceuticals, Inc. reported $730M of revenue over the trailing twelve months, +1.0% on the year before. 11 reported series are charted on this page, each one as filed.

$730M

Revenue, trailing twelve months · to Q2 2026 · +1.0% against the twelve months before

Net income: $79M
Net income · −42% year on year · trailing twelve months to Q2 2026
Free cash flow: $153M
Free cash flow · +36% year on year · trailing twelve months to Q2 2026
Operating margin: 16%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AMPH, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$730M	+1.0%	Q2 2026
Net income	$79M	−42%	Q2 2026
EPS	$1.69	−37%	Q2 2026
Gross margin	48%	n/a	Q2 2026
Operating margin	16%	n/a	Q2 2026
Net margin	11%	n/a	Q2 2026
ROE	12%	n/a	Q2 2026
ROA	5.5%	n/a	Q2 2026
ROIC	9.3%	n/a	Q2 2026
Free cash flow	$153M	+36%	Q2 2026
P/E	15.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.